The importance of MCL-1 as a potential therapeutic target in lymphoma is underscored by the limited clinical success of the BCL-2-inhibitor venetoclax, which achieved an overall response rate of 44% in a phase 1 clinical trial in Non-Hodgkin lymphoma (NHL) (MCL, 75%; FL, 38%; DLBCL, 18%) [102] and 26% in a real-world off-label NHL patient cohort [103]. This evidence concerns the gene BCL2 and mantle cell lymphoma.